Two Sigma Advisers
LXEO icon

Two Sigma Advisers’s Lexeo Therapeutics LXEO Stock Holding History

Two Sigma Advisers’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-81,300
Closed -$807K – 1224
2025
Q4 		$807K Buy
+81,300
New +$742K ﹤0.01% 1593
2025
Q2 		– Sell
-96,100
Closed -$333K – 2438
2025
Q1 		$333K Buy
+96,100
New +$426K ﹤0.01% 1950

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Advisers's LXEO Position: Q1 2026 in Review

Two Sigma Advisers sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 81,300 shares — an estimated $807K sold.

Two Sigma Advisers first reported a position in LXEO in Q1 2025 and held it in 2 quarters. The position peaked at $807K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Two Sigma Advisers reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 81,300 Lexeo Therapeutics shares in Q1 2026, an estimated $807K.
  • Two Sigma Advisers first reported a position in Lexeo Therapeutics in Q1 2025 and held it in 2 quarters.
  • Two Sigma Advisers's Lexeo Therapeutics position peaked at $807K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.